447 related articles for article (PubMed ID: 1611677)
1. Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists.
Kawakita T; Kuroita T; Yasumoto M; Sano M; Inaba K; Fukuda T; Tahara T
Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):624-30. PubMed ID: 1611677
[TBL] [Abstract][Full Text] [Related]
2. Benzoxazines. II. Synthesis, conformational analysis, and structure--activity relationships of 3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide derivatives as potent and long-acting serotonin-3 (5-HT3) receptor antagonists.
Kuroita T; Marubayashi N; Sano M; Kanzaki K; Inaba K; Kawakita T
Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2051-60. PubMed ID: 8945770
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of 6-chloro-3,4-dihydro-4-methyl-2H-1,4-benzoxazine-8-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists.
Kuroita T; Sakamori M; Kawakita T
Chem Pharm Bull (Tokyo); 1996 Apr; 44(4):756-64. PubMed ID: 8681408
[TBL] [Abstract][Full Text] [Related]
4. 5-HT3 receptor antagonists. 2. 4-Hydroxy-3-quinolinecarboxylic acid derivatives.
Hayashi H; Miwa Y; Ichikawa S; Yoda N; Miki I; Ishii A; Kono M; Yasuzawa T; Suzuki F
J Med Chem; 1993 Mar; 36(5):617-26. PubMed ID: 8496941
[TBL] [Abstract][Full Text] [Related]
5. The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist.
Fukuda T; Setoguchi M; Inaba K; Shoji H; Tahara T
Eur J Pharmacol; 1991 Apr; 196(3):299-305. PubMed ID: 1654255
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic activity of Y-25130 on 5-HT3 receptors.
Sato N; Sakamori M; Haga K; Takehara S; Setoguchi M
Jpn J Pharmacol; 1992 Aug; 59(4):443-8. PubMed ID: 1331590
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of 2,3-dihydrobenzofuran-7-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists.
Kuroita T; Yasumoto M; Inaba K; Sakamori M; Takehara S; Kawakita T
Chem Pharm Bull (Tokyo); 1994 Jan; 42(1):95-100. PubMed ID: 8124772
[TBL] [Abstract][Full Text] [Related]
8. Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides.
Youssefyeh RD; Campbell HF; Airey JE; Klein S; Schnapper M; Powers M; Woodward R; Rodriguez W; Golec S; Studt W
J Med Chem; 1992 Mar; 35(5):903-11. PubMed ID: 1548679
[TBL] [Abstract][Full Text] [Related]
9. Blockade of 5-HT3 receptor-mediated currents in dissociated frog sensory neurones by benzoxazine derivative, Y-25130.
Yakushiji T; Akaike N
Br J Pharmacol; 1992 Nov; 107(3):853-7. PubMed ID: 1472977
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.
Turconi M; Nicola M; Quintero MG; Maiocchi L; Micheletti R; Giraldo E; Donetti A
J Med Chem; 1990 Aug; 33(8):2101-8. PubMed ID: 1695682
[TBL] [Abstract][Full Text] [Related]
11. New 5-HT3 (serotonin-3) receptor antagonists. V. Synthesis and structure-activity relationships of pyrrolo[2,1-c][1,4]benzoxazine-6-carboxamides.
Kato M; Nishino S; Ito K; Yamakuni H; Takasugi H
Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1358-63. PubMed ID: 7553981
[TBL] [Abstract][Full Text] [Related]
12. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis.
Fernández AG; Puig J; Beleta J; Doménech T; Bou J; Berga P; Gristwood RW; Roberts DJ
Eur J Pharmacol; 1992 Nov; 222(2-3):257-64. PubMed ID: 1451737
[TBL] [Abstract][Full Text] [Related]
13. RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.
Eglen RM; Lee CH; Smith WL; Johnson LG; Whiting RL; Hegde SS
J Pharmacol Exp Ther; 1993 Aug; 266(2):535-43. PubMed ID: 8355189
[TBL] [Abstract][Full Text] [Related]
14. Prolonged anti-emetic activity and 5-HT3-receptor antagonism by BRL 46470 in conscious ferrets.
Bermudez J; Sanger GJ
J Pharm Pharmacol; 1994 Jun; 46(6):520-1. PubMed ID: 7932054
[TBL] [Abstract][Full Text] [Related]
15. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
Robertson DW; Lacefield WB; Bloomquist W; Pfeifer W; Simon RL; Cohen ML
J Med Chem; 1992 Jan; 35(2):310-9. PubMed ID: 1732548
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition by Y-25130 of the von Bezold-Jarisch effect evoked by 5-HT or 2-methyl-5-HT in anesthetized rats].
Inaba K; Morimoto Y; Fukuda T; Setoguchi M
Nihon Yakurigaku Zasshi; 1991 Oct; 98(4):293-9. PubMed ID: 1802816
[TBL] [Abstract][Full Text] [Related]
17. Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides.
Youssefyeh RD; Campbell HF; Klein S; Airey JE; Darkes P; Powers M; Schnapper M; Neuenschwander K; Fitzpatrick LR; Pendley CE
J Med Chem; 1992 Mar; 35(5):895-903. PubMed ID: 1312602
[TBL] [Abstract][Full Text] [Related]
18. New 5-HT3 (serotonin-3) receptor antagonists. IV. Synthesis and structure-activity relationships of azabicycloalkaneacetamide derivatives.
Kato M; Ito K; Nishino S; Yamakuni H; Takasugi H
Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1351-7. PubMed ID: 7553980
[TBL] [Abstract][Full Text] [Related]
19. [Effect of Y-25130, a selective 5-HT3 receptor antagonist, on the intestinal fluid secretion in rats].
Ooe M; Asano K; Haga K; Setoguchi M
Nihon Yakurigaku Zasshi; 1993 May; 101(5):299-307. PubMed ID: 8330800
[TBL] [Abstract][Full Text] [Related]
20. Benzimidazolone derivatives act as 5-HT4 receptor ligands in rat oesophagus.
Baxter GS; Clarke DE
Eur J Pharmacol; 1992 Mar; 212(2-3):225-9. PubMed ID: 1601064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
